General interest

The EAN Scientific Panel on Movement Disorders Management Group invites you to join us for the excellent Movement Disorders programme at EAN 2022, prepared in collaboration with the International Parkinson and Movement Disorder Society – European Section.

As part of the collaboration between EAN and EMEAC-IFCN, a clinical neurophysiology programme has been organised for 25-27 June at EAN 2022.

In January 2022, Prof. Wolfgang Grisold, from Vienna, Austria, became president of the World Federation of Neurology. To help our readers become better acquainted with the new WFN leader, we invited him to take part in a short interview.

We are delighted to announce the 2022 participants of the EAN Tournament for neurologists in training. Ten participants will make 6-minute presentations during our special Tournament Finals session at EAN 2022, which will also be broadcast live on EAN TV!

Following the election of new EAN Board members at EAN 2022, the newly composed board will appoint new chairs to the EAN Education Committee and the EAN Programme Committee.

Our highlighted selection of Covid-related cross-sectional case control studies from the scientific press for May 2022

Our highlighted selection of Covid-related obeservational studies from the scientific press for May 2022

Our highlighted selection of Covid-related meta-analyses and systemic reviews from the scientific press for May 2022

The overarching theme for EAN 2022 is ‘Getting Evidence into Practice’, which will be the subject of a range of workshops and symposia at the congress.

Following the election of the EAN Board on 25 June, the new board will be looking for new officers to join the ranks of its committees and working groups. Here's your chance to play a part in the future of neurology in Europe!

The EAN NeuroCOVID-19 Task Force has published a position paper on COVID-19 vaccination hesitancy among people with chronic neurological disorders in the European Journal of Neurology.

EAN Scientific Committee Chair, Prof. Thomas Berger, calls for members to join EAN's Scientific & Coordinating Panels, and provides an update on recent scientific activities.

Our authors of the month evaluated an experimental treatment for human prion disease, based on a fully humanised monoclonal antibody (PRN100) addressed against the cellular prion protein (PrP).

Our authors of the month conducted this retrospective case-control study in order to investigate the association of AD with the risk of COVID-19 infection (adjusted for comorbidities and sociodemographic factors).

Next in our series of interviews with presidents of National Neurological Societies, Prof. Jean-Philippe Azulay from the French Society of Neurology.